Calmark signs distributor agreement in Italy
Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with P.R.I.S.M.A. Srl (Prisma) in Italy. The agreement covers Calmark's test for assessment of COVID-19 disease severity and contains a minimum contract volume of EUR 457 500. The test, "Calmark COVID-19-LDH", is under development and is projected to obtain its CE mark approval during the first quarter of 2021, after which it will be ready for sale.
Prisma specializes in medical devices for laboratory diagnostics and is also active in research and veterinary medicine. The company sells products to the health care system throughout Italy, particularly to the major hospital regions but also to smaller and medium-sized hospitals and clinics. Over the course of the pandemic, Prisma has built up a product portfolio comprising the most important rapid tests for COVID-19 and is looking to expand it with additional complementary tests.
"We are delighted to complete this agreement, as the feedback we have received from the health care system indicates a tremendous need for Calmark's test for assessment of COVID-19 disease severity," says Silvia Palmieri Möller, Prisma's General Manager. "I am proud to be able to include this important product in our range and to provide it to the hospitals in Italy, which are in need of reliable tests to help assess the need of care for COVID-19 patients during the unfolding crisis."
"I have extensive experience of cooperating with Prisma, and their dedicated and professional work always impresses me," says Magdalena Tharaldsen, Calmark's Director International Business Development. "I am very pleased to be able to continue working with this distributor, and I know that Silvia and her team will do an excellent job in bringing our COVID-19 product to the Italian health care."
"Considering the high levels of transmission right now, it is extremely gratifying to be able to reach the whole of Italy with our LDH test for COVID-19 assessment," says Anna Söderlund, CEO of Calmark. "The agreement finalized today shows that prioritizing this test was the right decision."
This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13:45 CET on 26 November 2020.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.